Skip to content

Clinical efficacy of far-infrared tendon-soothing and blood-activating plaster in treating neck and shoulder pain

Clinical efficacy of far-infrared tendon-soothing and blood-activating plaster in treating neck and shoulder pain

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001144
Enrollment
Unknown
Registered
2026-05-07
Start date
2026-01-10
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neck and shoulder pain

Interventions

Treatment group:Acupuncture combined with TDP and far-infrared tendon-soothing and blood-activating plaster for treatment
Control group:Acupuncture combined with TDP

Sponsors

Fuzhou University Affiliated Provincial Hospital, No. 134 Dongjie, Gulou District, Fuzhou City, Fujian Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Age 18 to 65 years, regardless of gender. (2) Clearly diagnosed with neck and shoulder pain, accompanied by symptoms such as pain, stiffness, and limited range of motion in the neck and shoulder area. (3) Informed consent to this study, voluntarily agree to participate and sign the informed consent form. (4) No use of other pain treatment medications or physical therapy methods within 24 hours prior to treatment. Volunteers who meet the above criteria and have read and signed the informed consent form may be included.

Exclusion criteria

Exclusion criteria: (1) Individuals under 18 years of age or over 65 years of age. (2) Individuals with other serious primary diseases. (3) Individuals allergic to the components of the far-infrared tendon-soothing and blood-activating plaster. (4) Patients with malignant tumors, pregnant women, angina patients, and children. (5) Patients with severe heart, liver, kidney, or lung failure are contraindicated. (6) Individuals with open wounds at the treatment site. (7) Individuals unable to cooperate with the completion of treatment and evaluation. Individuals meeting any of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
VAS;NDI;

Countries

China

Contacts

Public Contactlinzhonghua

Fuzhou University Affiliated Provincial Hospital

doctor_lzh71@163.com13774511377

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026